• Merit Medical Systems recently announced that Sheri Lewis joined the company as Executive Vice President of Global Operations on August 31, 2026, bringing three decades of experience in global manufacturing, distribution, logistics, and supply chain management from firms including SkinHealth Systems, Avantor, Medtronic, and Honeywell.
• At the same time, long-time operations leader and former Chief Operating Officer Mr. Peterson shifted into a Senior Advisor role through March 5, 2027, creating an unusual blend of fresh operational leadership and structured continuity that could matter for Merit's complex global manufacturing footprint.
• We will now examine how Lewis’s deep background in large-scale global operations could influence Merit Medical Systems’ existing investment narrative and outlook.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Merit Medical Systems Investment Narrative Recap

To own Merit Medical Systems, you need to believe its mix of interventional and therapeutic devices can keep gaining share while margins hold up against higher costs and pricing pressure. In the near term, the key catalyst remains progress on WRAPSODY reimbursement, while the biggest risk is still execution and quality across a broad, global manufacturing base. The Sheri Lewis appointment looks directionally helpful to that operational risk, but likely does not change the near term catalyst in a material way.

Against this backdrop, the recent Class I and Class II recalls in the renal and guidewire portfolio are highly relevant to Lewis’s arrival. Her background in quality, regulatory, and operational excellence at large manufacturers now sits squarely against a real world test: keeping product quality high and recalls contained while Merit continues to scale. How effectively operations leadership stabilizes quality will matter for both margin resilience and investor confidence in the current growth plan.

Yet, while the long term opportunity is appealing, investors should also be aware that quality and recall risk could...

Merit Medical Systems’ narrative projects $1.9 billion revenue and $226.4 million earnings by 2029. This requires 6.3% yearly revenue growth and an earnings increase of about $80.8 million from $145.6 million today.

Uncover how Merit Medical Systems' forecasts yield a $100.27 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already more cautious, assuming around US$1.9 billion of revenue and US$225.1 million of earnings by 2029, and focusing on how recurring product and supply chain issues could keep margins closer to current levels. Compared with the baseline view, they represent a meaningfully more pessimistic narrative, and leadership changes in global operations may prompt you to revisit which of these outlooks feels closer to your own.

Explore 2 other fair value estimates on Merit Medical Systems - why the stock might be worth as much as 32% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Merit Medical Systems research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Merit Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merit Medical Systems' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.